The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: A systematic review

European Journal of Clinical Pharmacology

Volumn 72, Issue 1, 2016, Pages 83-91

  Chandrasekhar, Jaya ^a,b   Hibbert, Benjamin ^a   Froeschl, Michael ^a   So, Derek ^a   Mehran, Roxana ^a   May, Michel Le ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acute coronary syndrome; P2Y12 receptor blockers; Percutaneous coronary intervention; Switching

Indexed keywords

CLOPIDOGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CONTINUOUS INFUSION; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; INCIDENCE; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED;

CARDIOVASCULAR DISEASES; HEMORRHAGE; HOSPITALIZATION; HUMANS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE;

EID: 84953306457     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1949-1     Document Type: Article

References (37)

1. Jneid H, Anderson JL, Wright RS et al (2012) ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol 60(7):645-681
2. Hamm CW, Bassand JP, Agewall S et al (2012) [ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the european society of cardiology (ESC)]. G Ital Cardiol (Rome) 13(3):171-228
3. Bagai A, Wang Y, Wang TY et al (2014) In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. Circ Cardiovasc Interv 7(4):585-593
4. Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045-1057
5. Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001-2015
6. Bagai A, Peterson ED, Honeycutt E et al (2014) In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. Eur Heart J Acute Cardiovasc Care. doi: 10.1177/2048872614564082
7. Wiviott SD, Braunwald E, Angiolillo DJ et al (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 118(16):1626-1636
8. Montalescot G, Wiviott SD, Braunwald E et al (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373(9665):723-731
9. Simard THB, Ramirez FD, Froeschl M, Chen YX, O'Brien ER (2014) The evolution of coronary stents: a brief review. Can J Cardiol 30(1):35-45
10. Hibbert B, MacDougall A, Labinaz M et al (2012) Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry. Circ Cardiovasc Interv 5(6):805-812
11. Amin AP, Bachuwar A, Reid KJ et al (2013) Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. J Am Coll Cardiol 61(21):2130-2138
12. Ramirez FD, Hibbert B, Simard T et al (2012) Natural history and management of aortocoronary saphenous vein graft aneurysms: a systematic review of published cases. Circulation 126(18):2248-2256
13. Wells GA, SB, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P, (2010) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses
14. De Luca G, Verdoia M, Schaffer A et al (2014) Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience. J Thromb Thrombolysis 38(3):388-394
15. Almendro-Delia, M, Blanco Ponce, E, Gomez-Dominguez, R, et al., (2014) Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. J Thromb Thrombolysis
16. Clemmensen P, Grieco N, Ince H, et al. (2014) MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel - the European MULTIPRAC Registry. Eur Heart J Acute Cardiovasc Care
17. Alexopoulos D, Xanthopoulou I, Deftereos S et al (2014) In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. Am Heart J 167(1):68-76, e2
18. Parodi G, De Luca G, Bellandi B et al (2014) Switching from clopidogrel to prasugrel in patients having coronary stent implantation. J Thromb Thrombolysis 38(3):395-401
19. Loh JP, Pendyala LK, Kitabata H et al (2013) Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 111(6):841-845
20. Collet JP, Silvain J, Bellemain-Appaix A, Montalescot G (2014) Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome: an outdated and harmful strategy. Circulation 130(21):1904-1914, discussion 1914
21. Diodati JG, Saucedo JF, Cardillo TE et al (2014) Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial. Thromb Haemost 112(2):311-322
22. Gurbel PA, Bliden KP, Butler K et al (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120(25):2577-2585
23. Angiolillo DJ, Saucedo JF, Deraad R et al (2010) Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 56(13):1017-1023
24. Hibbert B, Maze R, Pourdjabbar A et al (2014) A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study. PLoS One 9(3), e92078
25. Moudgil R, Al-Turbak H, Osborne C et al (2014) Superiority of ticagrelor over clopidogrel in patients after cardiac arrest undergoing therapeutic hypothermia. Can J Cardiol 30(11):1396-1399
26. Mehran R, Pocock SJ, Stone GW et al (2009) Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 30(12):1457-1466
27. Eikelboom JW, Mehta SR, Anand SS et al (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114(8):774-782
28. Alexopoulos D, Stavrou K, Koniari I et al (2014) Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events. Thromb Haemost 112(3):551-557
29. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107(23):2908-2913
30. Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360(4):354-362
31. Wiviott SD, Trenk D, Frelinger AL et al (2007) Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116(25):2923-2932
32. Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119(19):2553-2560
33. Cayla G, Cuisset T, Silvain J et al (2014) Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: design of the randomized antarctic study. Am Heart J 168(5):674-681
34. Wiviott SD, White HD, Ohman EM et al (2013) Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet 382(9892):605-613
35. Levine GN, Bates ER, Blankenship JC et al (2011) ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation 124(23):e574-e651
36. Bonaca MP, Bhatt DL, Braunwald E et al (2014) Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 167(4):437-444, e5
37. Roberts JD, Wells GA, Le May MR et al (2012) Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 379(9827):1705-1711